Aquestive therapeutics, inc. (AQST)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17Jun'17
Revenues

48,731

52,609

53,014

53,863

56,662

67,430

0

0

0

-

-

Revenues

-

-

-

-

-

-

-

-

-

0

0

Costs and expenses:
The aggregate costs incurred in the production of goods and supply for sale.

20,514

20,361

18,356

19,305

18,858

20,988

0

0

0

0

0

Research and development

20,625

20,574

23,200

22,671

22,514

23,112

0

0

0

0

0

Selling, general and administrative

61,047

64,342

66,554

65,186

82,608

72,269

0

0

0

0

0

Total costs and expenses

102,186

105,277

108,110

107,162

123,980

116,369

0

0

0

0

0

Loss from operations

-53,455

-52,668

-55,091

-53,294

-67,313

-48,934

0

0

0

0

0

Other income/(expenses):
Interest expense

10,163

9,318

8,439

7,720

7,710

7,711

0

0

0

0

0

Interest income

464

636

877

955

802

552

0

0

0

0

-

Loss on the extinguishment of debt

-

-

0

-

-

-

0

-

-

-

-

Change in fair value of warrant

-

-

0

4,116

-

5,278

0

0

0

0

0

Other, net

-

-

-

-

-

-

-

-

-

0

0

Net loss before income taxes

-68,050

-66,246

-67,554

-64,180

-80,201

-61,376

0

0

0

0

0

Income taxes

0

0

0

0

0

0

0

0

0

0

0

Net loss

-68,050

-66,246

-67,554

-64,180

-80,201

-61,376

0

0

0

0

0

Dividends on redeemable preferred interests

-

-

-

-

-

-

-

-

-

0

0

Net loss attributable to common shares/ members' interests

-

-

-

-

-

-

-

-

-

0

0

Comprehensive loss

-68,050

-66,246

-67,554

-64,180

-80,201

-61,376

0

0

0

0

0

Net loss per share - basic and diluted (in dollars per share)

-0.49

-0.46

-0.74

-0.82

-0.59

-0.69

-0.64

-1.90

0.27

-

-

Weighted-average number of common shares outstanding - basic and diluted (in shares)

33,569

26,448

25,031

24,980

24,963

24,989

23,646

19,188

15,077

-

-